Video

TAK-700 in Localized Prostate Cancer Clinical Trials

Author(s):

Howard M. Sandler, MD

Dr. Howard Sandler from Cedars-Sinai Medical Center discusses the TAK-700 in Localized Prostate Cancer Clinical Trials

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses the examination of hormonal and radiation therapy used in combination for localized prostate cancer. A new agent named TAK-700 is being examined in multiple studies for various types of prostate cancer.

Related Videos
Yungan Tao, MD
Jared Weiss, MD
Guru P. Sonpavde, MD
Martin H. Voss, MD
Sally Lau, MD
Hope S. Rugo, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC
Related Content
Darolutamide Plus ADT in mHSPC: © vitanovski - stock.adobe.com
October 14th 2024

EU Approval Sought for Darolutamide Plus ADT for mHSPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Neeraj Agarwal, MD, FASCO
October 10th 2024

Talazoparib Plus Enzalutamide Improves OS in mCRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

John Michael Bryant, MD
October 8th 2024

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

Neeraj Agarwal, MD, FASCO
October 8th 2024

PARP1-Selective Inhibitors Generate Excitement in Solid Tumors